Table 1c.
Publications relevant to ML methods used for cancer survival prediction.
Publication | ML method | Cancer type | No of patients | Type of data | Accuracy | Validation method | Important features |
---|---|---|---|---|---|---|---|
Chen Y-C et al. [50] | ANN | Lung cancer | 440 | Clinical, gene expression | 83.5% | Cross validation | Sex, age, T_stage, N_stage LCK and ERBB2 genes |
Park K et al. [26] | Graph-based SSL algorithm | Breast cancer | 162,500 | SEER | 71% | 5-fold cross validation | Tumor size, age at diagnosis, number of nodes |
Chang S-W et al. [32] | SVM | Oral cancer | 31 | Clinical, genomic | 75% | Cross validation | Drink, invasion, p63 gene |
Xu X et al. [51] | SVM | Breast cancer | 295 | Genomic | 97% | Leave-one-out cross validation | 50-gene signature |
Gevaert O et al. [52] | BN | Breast cancer | 97 | Clinical, microarray | AUC = 0.851 | Hold-Out | Age, angioinvasion, grade MMP9, HRASLA and RAB27B genes |
Rosado P et al. [53] | SVM | Oral cancer | 69 | Clinical, molecular | 98% | Cross validation | TNM_stage, number of recurrences |
Delen D et al. [54] | DT | Breast cancer | 200,000 | SEER | 93% | Cross validation | Age at diagnosis, tumor size, number of nodes, histology |
Kim J et al. [36] | SSL Co-training algorithm | Breast cancer | 162,500 | SEER | 76% | 5-fold cross validation | Age at diagnosis, tumor size, number of nodes, extension of tumor |